AU2001261828A1 - Compositions containing diacyltartaric salts of (E)-metanicotine - Google Patents

Compositions containing diacyltartaric salts of (E)-metanicotine

Info

Publication number
AU2001261828A1
AU2001261828A1 AU2001261828A AU6182801A AU2001261828A1 AU 2001261828 A1 AU2001261828 A1 AU 2001261828A1 AU 2001261828 A AU2001261828 A AU 2001261828A AU 6182801 A AU6182801 A AU 6182801A AU 2001261828 A1 AU2001261828 A1 AU 2001261828A1
Authority
AU
Australia
Prior art keywords
tartaric acid
methyl
amine
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261828A
Other languages
English (en)
Inventor
Gary Maurice Dull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalyst Biosciences Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of AU2001261828A1 publication Critical patent/AU2001261828A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001261828A 2000-07-14 2001-05-04 Compositions containing diacyltartaric salts of (E)-metanicotine Abandoned AU2001261828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/616,187 US6743812B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
US09616187 2000-07-14
PCT/US2001/040689 WO2002005801A2 (en) 2000-07-14 2001-05-04 Compositions containing diacyltartaric salts of (e)-metanicotine

Publications (1)

Publication Number Publication Date
AU2001261828A1 true AU2001261828A1 (en) 2002-01-30

Family

ID=24468381

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261828A Abandoned AU2001261828A1 (en) 2000-07-14 2001-05-04 Compositions containing diacyltartaric salts of (E)-metanicotine

Country Status (13)

Country Link
US (1) US6743812B1 (no)
EP (1) EP1317267A2 (no)
JP (1) JP2004503589A (no)
CN (1) CN1452486A (no)
AU (1) AU2001261828A1 (no)
BR (1) BR0112131A (no)
CA (1) CA2415906A1 (no)
HU (1) HUP0301594A2 (no)
IL (1) IL153487A0 (no)
NO (1) NO20030156L (no)
PL (1) PL365602A1 (no)
WO (1) WO2002005801A2 (no)
ZA (1) ZA200300132B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
CN101528698A (zh) * 2006-05-09 2009-09-09 阿斯利康公司 (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TW200829244A (en) * 2006-09-15 2008-07-16 Astrazeneca Ab Therapeutic combinations 482
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
JP2010535237A (ja) * 2007-07-31 2010-11-18 ターガセプト・インコーポレイテッド （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与
CA2799650A1 (en) 2010-05-20 2011-11-24 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
CA2206119C (en) * 1994-12-12 2008-05-13 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
ATE334120T1 (de) 1995-01-06 2006-08-15 Targacept Inc Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
CA2197838C (en) * 1996-03-01 2004-09-28 Mark S. Miller Mouthfeel and lubricity enhancing composition
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds

Also Published As

Publication number Publication date
ZA200300132B (en) 2004-04-06
HUP0301594A2 (hu) 2003-08-28
IL153487A0 (en) 2003-07-06
BR0112131A (pt) 2003-09-02
PL365602A1 (en) 2005-01-10
US6743812B1 (en) 2004-06-01
CN1452486A (zh) 2003-10-29
WO2002005801A2 (en) 2002-01-24
JP2004503589A (ja) 2004-02-05
EP1317267A2 (en) 2003-06-11
CA2415906A1 (en) 2002-01-24
WO2002005801A3 (en) 2002-08-08
NO20030156L (no) 2003-03-13
NO20030156D0 (no) 2003-01-13

Similar Documents

Publication Publication Date Title
US6492399B1 (en) Pharmaceutical compositions and methods for use
EP2371818B1 (en) Hydroxybenzoate salts of metanicotine compounds
US6455554B1 (en) Oxopyridinyl pharmaceutical compositions and methods for use
EP1086082B9 (en) Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
US8778978B2 (en) Hydroxybenzoate salts of metanicotine compounds
EP1185514A1 (en) Pharmaceutical compositions and methods for use
US6743812B1 (en) Pharmaceutical compositions and methods for use
US7045538B2 (en) Compounds capable of activating cholinergic receptors
EP1311265B1 (en) Pharmaceutical compositions for treating neurological disorders
AU2002222909A1 (en) Pharmaceutical compositions for treating neurological disorders
US7060826B2 (en) Compounds capable of activating cholinergic receptors
AU2006202005B2 (en) Pharmaceutical compositions for treating neurological disorders
US20030087915A1 (en) Pharmaceutical compositions and methods for use